Celgene Tells Fed. Circ. Chemo IP Row Deserved Dismissal
Drugmaker Celgene Corp. urged a Federal Circuit panel to affirm the dismissal of Andrulis Pharmaceuticals' chemotherapy patent infringement allegations Friday, maintaining the Delaware trial judge correctly found the claims unpatentably vague...To view the full article, register now.
Already a subscriber? Click here to view full article